Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  International Journal of Oncology

• Publication date

  2010-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/IJO-00000639PMID 20428777
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

  2009cited by this paper
• Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth.

  2009cited by this paper
• Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.

  2009cited by this paper
• Twist promotes tumor cell growth through YB-1 expression.

  2008cited by this paper
• Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to Imatinib in Chronic Myeloid Leukemia

  2008cited by this paper
• Tip60 Is Regulated by Circadian Transcription Factor Clock and Is Involved in Cisplatin Resistance*

  2008cited by this paper
• Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

  2008cited by this paper
• Ets regulates peroxiredoxin1 and 5 expressions through their interaction with the high‐mobility group protein B1

  2008cited by this paper
• Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells

  2008cited by this paper
• Twist and p53 reciprocally regulate target genes via direct interaction

  2008cited by this paper
• Mutant FLT 3 : A Direct Target of Sorafenib in Acute Myelogenous Leukemia

  2008cited by this paper
• Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.

  2007cited by this paper
• Signal integration in the endoplasmic reticulum unfolded protein response

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Translational Control and the Unfolded Protein Response

  2007cited by this paper
• The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress

  2007cited by this paper
• Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.

  2007cited by this paper
• Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

  2006cited by this paper
• Molecular targeting therapy for renal cell carcinoma

  2006cited by this paper
• Endoplasmic reticulum stress signaling in disease.

  2006cited by this paper
• Sorafenib for the Treatment of Advanced Renal Cell Carcinoma

  2006cited by this paper
• Coping with stress: eIF2 kinases and translational control.

  2006cited by this paper
• Translational control in stress and apoptosis

  2005cited by this paper
• Targeted agents for the treatment of advanced renal cell carcinoma.

  2005cited by this paper
• A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

  2005cited by this paper
• Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation

  2005cited by this paper
• Targeted agents for the treatment of advanced renal cell carcinoma

  2005cited by this paper
• Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

  2005cited by this paper
• High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

  2005cited by this paper
• A small molecule–kinase interaction map for clinical kinase inhibitors

  2005cited by this paper
• The anti-angiogenic basis of metronomic chemotherapy

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors

  2004cited by this paper
• Active transport of imatinib into and out of cells: implications for drug resistance.

  2004cited by this paper
• Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response

  2004cited by this paper
• Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells.

  2004cited by this paper
• The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer

  2004cited by this paper
• Nrf2 Is a Direct PERK Substrate and Effector of PERK-Dependent Cell Survival

  2003cited by this paper
• Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.

  2003cited by this paper
• An integrated stress response regulates amino acid metabolism and resistance to oxidative stress.

  2003cited by this paper
• The mammalian unfolded protein response.

  2003cited by this paper
• Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma.

  2003cited by this paper
• Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.

  2002cited by this paper
• Gene-specific regulation by general translation factors.

  2002cited by this paper
• von Hippel‐Lindau tumor suppressor protein represses platelet‐derived growth factor B‐chain gene expression via the Sp1 binding element in the proximal PDGF‐B promoter

  2002cited by this paper
• Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.

  2002cited by this paper
• BAY 43-9006: preclinical data.

  2002cited by this paper
• Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.

  2001cited by this paper
• Discovery of a novel Raf kinase inhibitor.

  2001cited by this paper
• Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.

  2000cited by this paper
• Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

  2000cited by this paper
• Phase II Trial of Interleukin 2, Interferon α, and 5-Fluorouracil in Metastatic Renal Cell Cancer: A Cytokine Working Group Study

  2000cited by this paper
• Characterization of a Mutant Pancreatic eIF-2α Kinase, PEK, and Co-localization with Somatostatin in Islet Delta Cells*

  1999cited by this paper
• Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.

  1999cited by this paper
• Establishment of two human renal cell carcinoma cell lines with different chemosensitivity.

  1996cited by this paper
• Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

  1995cited by this paper
• Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

  1995cited by this paper
• Human recombinant interferons‐beta and ‐gamma decrease gelatinase production and invasion by human KG‐2 renal‐carcinoma cells

  1994cited by this paper
• Development of mechanisms of protection against oxidative stress in doxorubicin-resistant rat tumoral cells in culture.

  1990cited by this paper
• Different growth pattern and biologic behavior of human renal cell carcinoma implanted into different organs of nude mice.

  1987cited by this paper
• Human renal cell carcinoma: establishment and characterization of two new cell lines.

  1982cited by this paper

• Modulation of endoplasmic reticulum stress response in gut-origin encephalopathy: Impact of vascular endothelial growth factor receptor-2 manipulation.

  2020cites this paper
• Understanding shared pathogenesis between chronic obstructive pulmonary disease (COPD) and lung cancer by means of cell specific genomics

  2018cites this paper
• Synergistic combination of YS-1 and adriamycin inhibits human renal cancer through ERK1/2 signaling pathway in vitro and in vivo.

  2017cites this paper
• Carcinomes rénaux : caractérisation moléculaire et des voies métaboliques dépendant des mécanismes hypoxiques

  2015cites this paper
• Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells

  2015cites this paper
• Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib

  2014cites this paper
• The Relevance of Testing the Efficacy of Anti-Angiogenesis Treatments on Cells Derived from Primary Tumors: A New Method for the Personalized Treatment of Renal Cell Carcinoma

  2014cites this paper
• GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC).

  2012cites this paper
• Vitiligo inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8

  2012cites this paper
• Evaluation of Daily Oral Kinase Inhibitors in Pediatric SPNET Tumor Xenografts

  2012cites this paper
• Current world literature.

  2011cites this paper
• Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression

  2011cites this paper
• Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation.

  2010cites this paper